Towards third generation matrix metalloproteinase inhibitors for cancer therapy

The failure of matrix metalloproteinase (MMP) inhibitor drug clinical trials in cancer was partly due to the inadvertent inhibition of MMP antitargets that counterbalanced the benefits of MMP target inhibition. We explore how MMP inhibitor drugs might be developed to achieve potent selectivity for v...

Descripción completa

Detalles Bibliográficos
Autores principales: Overall, C M, Kleifeld, O
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361222/
https://www.ncbi.nlm.nih.gov/pubmed/16538215
http://dx.doi.org/10.1038/sj.bjc.6603043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361222/
https://www.ncbi.nlm.nih.gov/pubmed/16538215
http://dx.doi.org/10.1038/sj.bjc.6603043

Ejemplares similares